[{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvelle Therapeutics Announces Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$822.0 million","upfrontCash":"Undisclosed","newsHeadline":"SK Biopharmaceuticals Emerges from Pandemic Delays with Pitch for $822M IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.81999999999999995,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.81999999999999995,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$800.0 million","upfrontCash":"Undisclosed","newsHeadline":"SK Biopharmaceuticals Set to Make Historic IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"NaV Channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.80000000000000004,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cenobamate Designated Promising Innovative Medicine (PIM) by the UK\u2019s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$506.0 million","upfrontCash":"$47.0 million","newsHeadline":"SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.51000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.51000000000000001,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"European Medicines Agency","pharmaFlowCategory":"D","amount":"$207.8 million","upfrontCash":"Undisclosed","newsHeadline":"Arvelle Announces Closing of Final Tranche of Series A Financing Round","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ European Medicines Agency","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ European Medicines Agency"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK life science Presents Latest Cenobamate Data at the American Epilepsy Society AES2020 Virtual Event","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","amount":"$960.0 million","upfrontCash":"$960.0 million","newsHeadline":"Angelini Pharma Acquires Arvelle Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0.95999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.95999999999999996,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ Angelini Pharma"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cenobamate Receives Positive CHMP Opinion for Adjunctive Treatment of Focal-Onset (Partial-Onset) Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ S.K Biopharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Therapeutics \/ S.K Biopharmaceutical"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONTOZRY\u00ae (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epilepsia Publishes Two Post-hoc Analyses from Long-Term Study of XCOPRI\u00ae (Cenobamate Tablets) CV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Life Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Life Science \/ Not Applicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK life Science to Present Latest XCOPRI\u00ae (cenobamate tablets) CV Data at the American Academy of Neurology 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Life Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Life Science \/ Not Applicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cenobamate (ONTOZRY\u00ae), for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults, Is Now Available in the Netherlands","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Not Applicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Term Efficacy and Safety Data of XCOPRI\u00ae (cenobamate tablets) CV Published in Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Life Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Life Science \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"$15.0 million","newsHeadline":"SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Eurofarma","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Eurofarma"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cenobamate (ONTOZRY\u00ae), for the Treatment of Uncontrolled Focal-onset Seizures in Adults, Is Now Available in France and Belgium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Angelini Pharma"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Announces Approval of XCOPRI (cenobamate tablets) in Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Korea's SK Biopharma Enters MENA Through Strategic Partnership with Hikma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SK Biopharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo's Paladin Labs Announces Launch of XCOPRI\u00ae (cenobamate tablets) in Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XCOPRI\u00ae (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biopharmaceuticals \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Cenobamate
Details :
Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Details :
Xcopri (cenobamate) is a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel. It is approved as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy.
Details :
Under the terms of the agreement, Hikma will have priority rights for the commercialisation and manufacture of SK Biopharmaceuticals’ current and future pipeline of innovative products for 17 countries in the MENA region.
Details :
XCOPRI™ (cenobamate tablets) inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel, which is used for partial-onset seizures in adults with epilepsy.
Details :
Cenobamate – under the brand name ONTOZRY® – has been commercialized in five major European countries such as Germany, the UK, Italy, Spain, and France, accounting for about 73 percent of the total value of the continent’s epilepsy market.
Details :
Ontozry (cenobamate) is a novel small molecule that provides a dual, complementary mechanism of action aimed at treatment of seizures also known as focal-onset seizures.
Details :
Under the terms of agreement, SK Biopharmaceuticals has granted Eurofarma the exclusive rights to develop and commercialize Xcopri (cenobamate) in Latin America. SK Biopharmaceuticals will now be present in four continents: North America, Europe, Asia, a...
Details :
The open-label extension of Study C017 demonstrated high response rates with no new safety signals identified in patients receiving XCOPRI (cenobamate) for up to 4 years.
Details :
Pivotal trial has demonstrated that Ontozry (cenobamate) at doses of 100 mg, 200 mg, and 400 mg/day significantly improved seizure control versus placebo for adult patients with focal-onset seizures taking 1-3 ASMs.
Details :
XCOPRI® (cenobamate tablets) CV, is an anti-seizure medication (ASM), a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents.
Market Place
Reset All
